文献速递头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

分子谱分析揭示黑色素瘤脑转移独特的免疫与代谢特征

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
PubMed 文献 · Cancer Discov · 2019-02-20

研究对88例切除的黑色素瘤脑转移灶和42例患者匹配的颅外转移灶进行RNA测序,部分行全外显子测序、T细胞受体测序和免疫组化。脑转移灶免疫浸润异质性与既往放疗和开颅术后生存相关,并显示免疫抑制和氧化磷酸化富集。氧化磷酸化抑制剂IACS-010759改善MAPK抑制剂耐药颅内黑色素瘤异种移植小鼠生存并抑制脑转移形成。

要点

  • 黑色素瘤脑转移灶免疫浸润具异质性,与既往放疗和开颅术后生存相关。
  • 与患者匹配颅外转移灶相比,脑转移灶呈免疫抑制和氧化磷酸化基因表达富集。
  • 氧化磷酸化抑制剂IACS-010759改善MAPK抑制剂耐药颅内异种移植小鼠生存并抑制脑转移形成。

核心结论

  • 黑色素瘤脑转移具有独特的免疫和代谢特征,为发病机制和治疗耐药提供新见解。

研究设计与样本

  • 对88例切除的黑色素瘤脑转移灶和42例患者匹配的颅外转移灶行RNA测序,组织充足者行全外显子测序、T细胞受体测序和免疫组化。
  • 基因表达分析涵盖颅内和皮下异种移植及自发黑色素瘤脑转移模型,并行直接代谢物谱分析和体内[U-13C]-葡萄糖示踪。

主要发现

  • 黑色素瘤脑转移灶免疫浸润异质性与既往放疗和开颅术后生存相关。
  • 与患者匹配颅外转移灶相比,脑转移灶显示显著免疫抑制和氧化磷酸化富集。
  • 颅内和皮下异种移植及自发脑转移模型的基因表达分析证实脑转移灶氧化磷酸化基因表达增加,直接代谢物谱分析和体内[U-13C]-葡萄糖示踪也检测到该增加。

临床怎么用

  • 氧化磷酸化抑制剂IACS-010759改善携带MAPK抑制剂耐药颅内黑色素瘤异种移植小鼠的生存,并抑制自发脑转移模型中的脑转移形成。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a critical need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor sequencing, and IHC. MBMs demonstrated heterogeneity of immune infiltrates that correlated with prior radiation and post-craniotomy survival. Comparison with patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs. Gene-expression analysis of intracranial and subcutaneous xenografts, and a spontaneous MBM model, confirmed increased OXPHOS gene expression in MBMs, which was also detected by direct metabolite profiling and [U-13C]-glucose tracing in vivo. IACS-010759, an OXPHOS inhibitor currently in early-phase clinical trials, improved survival of mice bearing MAPK inhibitor-resistant intracranial melanoma xenografts and inhibited MBM formation in the spontaneous MBM model. The results provide new insights into the pathogenesis and therapeutic resistance of MBMs. SIGNIFICANCE: Improving our understanding of the pathogenesis of MBMs will facilitate the rational development and prioritization of new therapeutic strategies. This study reports the most comprehensive molecular profiling of patient-matched MBMs and extracranial metastases to date. The data provide new insights into MBM biology and therapeutic resistance.See related commentary by Egelston and Margolin, p. 581.This article is highlighted in the In This Issue feature, p. 565.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Fischer GM, Jalali A, Kircher DA, et al. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019. PMID: 30787016. doi:10.1158/2159-8290.CD-18-1489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。